Natural history and ecology of Fowler's toad, Bufo woodhousei fowleri (Amphibia: Bufonidae), in the Indiana Dunes National Lakeshore / by Felix Breden.

n.s. no.49(1988)

A new generic and family position for Bufo Borbonica, by D. Dwight Davis.

v.20:no.12(1935)

A new species of toad (Bufo) from Sierra Leone [by] Robert F. Inger [and] J. I. Menzies.

v.39:no.54(1961)

Examples of retracts in a free group that are not the fixed subgroup of any group of automorphisms

Let F be a free group of rank at least three. We show that some retracts of F previously studied by Martino-Ventura are not equal to the fixed subgroup of any group of automorphisms of F. This shows that, in F, there exist subgroups that are equal to the fixed subgroup of some set of endomorphisms but are not equal to the fixed subgroup of any set of automorphisms. Moreover, we determine the Galois monoids of these retracts, where, by the Galois monoid of a subgroup H of F, we mean the monoid consisting of all endomorphisms of F that fix H.

Estudo sôbre hemoparasitos de Bufo marinus L. da Venezuela: 1. Hemogregarinas - - 2. Uma nova espécie de Toxoplasma

Faz-se uma revisão das espécies de Haemogregarina, encontradas, até a presente data, em Bufo marinus L. da região Norte, Leste e Sul da Venezuela,descrevendo-se o ciclo agâmico da Haemogregarina darlingi Leger, 1918, o ciclo esquizogônico da Haemogregarina aquai Phisalix, 1930, propondo-se seja denominada Karyolysus aquai (Phisalix) por realizar o ciclo agâmico nas células endoteliais. Descreve-se a Haemogregarina legeri nov. sp. Estuda-se um Toxoplasma no sangue e vísceras de Bufo marinus L., descrevendo-se a anatomia patológica dos órgãos afetados, discutindo-se o estado atual da sistemática das espécies de Toxoplasma, parasitos de vertebrados poikilotermos, propondo-se o nome de Toxoplasma serpai nov. sp. para êste protozoário.

Quasi-Potency and Cyclic subgroup separability

We study the profinite topology on discrete groups and in particular the property of cyclic subgroup separability. We investigate the class of quasi-potent, cyclic subgroup separable groups, producing many examples and showing how it behaves with respect to certain group constructions.

Toddia sp., "corpúsculo paranuclear" no sangue de Leptodactylus e Bufo do Brasil: desenvolvimento e citoquímica

O gênero Toddia, criado por França 1911, para um organismo encontrado em eritrõcitos de um anfíbio anuro, tem estrutura particular e o problema de sua natureza (protozoário ou vírus) é discutido. Nosso resultados mostram reações Feulgen e Verde Metila positivas, principalmente no início da infecção. Com o decorrer da infecção as partículas são, geralmente, maiores que aquelas observadas alguns dias após as inoculações, mas as reações citoquímicas citadas anteriormente são, em geral, negativas ou fracamente positivas. Os mesmos resultados foram obtidos quando empregamos Laranja de acridina para caracterização do DNA e esta técnica foi negativa para o RNA. Estudando o desenvolvimento deste organismo e seus efeitos infecciosos foram confirmados por inoculações experimentais. As alterações no sangue do hospedeiro foram observadas e notamos que o núclo dos eritrócitos é severamente alterado durante o desenvolvimento da infecção, que é geralmente, muito intensa, terminando com a morte do hospedeiro. As inoculações experimentais demonstraram a especificidade da infecção, e diante dos conhecimentos a respeito dos organismos deste gênero, discutimos o problema da criação de espécies.

Uma nova hemogregarina no sangue de Bufo crucifer wied, 1821 do Brasil

A ocorrência de hemagregarinas no sangue dos sapos que examinamos (Bufo crucifer, B. marinus e Melanophryniscus moreirae) revelou-se extremamente rara; apenas um exemplar de B. crucifer procedente de Manguinhos (Rio de Janeiro, Guanabara) apresentou-se parasitado. As formas sanguíneas encontradas eram intra-eritrocitárias, medindo em média 10,8/ 3,6µ; não as identificamos como trofozoítos ou gametócitos e discutimos este fato. As hemácias parasitadas tinham dimensões normais, porém podiam ter o núcleo deslocado. Supomos ser esta a primeira referência a hemogregarinas neste hospedeiro. Não encontramos identidade entre as formas que descrevemos e aquelas referidas em outras espécies de sapos; fornecemos uma lista das hemogregarinas achadas nestes hospedeiros. Denominamos provisoriamente os parasitos que encontramos Haemogregarina "sensu lato", até que novos dados sobre seu ciclo evolutivo sejam conhecidos.

Subgroup analyses in randomised controlled trials: cohort study on trial protocols and journal publications

OBJECTIVE: To investigate the planning of subgroup analyses in protocols of randomised controlled trials and the agreement with corresponding full journal publications. DESIGN: Cohort of protocols of randomised controlled trial and subsequent full journal publications. SETTING: Six research ethics committees in Switzerland, Germany, and Canada. DATA SOURCES: 894 protocols of randomised controlled trial involving patients approved by participating research ethics committees between 2000 and 2003 and 515 subsequent full journal publications. RESULTS: Of 894 protocols of randomised controlled trials, 252 (28.2%) included one or more planned subgroup analyses. Of those, 17 (6.7%) provided a clear hypothesis for at least one subgroup analysis, 10 (4.0%) anticipated the direction of a subgroup effect, and 87 (34.5%) planned a statistical test for interaction. Industry sponsored trials more often planned subgroup analyses compared with investigator sponsored trials (195/551 (35.4%) v 57/343 (16.6%), P<0.001). Of 515 identified journal publications, 246 (47.8%) reported at least one subgroup analysis. In 81 (32.9%) of the 246 publications reporting subgroup analyses, authors stated that subgroup analyses were prespecified, but this was not supported by 28 (34.6%) corresponding protocols. In 86 publications, authors claimed a subgroup effect, but only 36 (41.9%) corresponding protocols reported a planned subgroup analysis. CONCLUSIONS: Subgroup analyses are insufficiently described in the protocols of randomised controlled trials submitted to research ethics committees, and investigators rarely specify the anticipated direction of subgroup effects. More than one third of statements in publications of randomised controlled trials about subgroup prespecification had no documentation in the corresponding protocols. Definitive judgments regarding credibility of claimed subgroup effects are not possible without access to protocols and analysis plans of randomised controlled trials.

Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

BACKGROUND: Patients with rheumatoid arthritis (RA) with an inadequate response to TNF antagonists (aTNFs) may switch to an alternative aTNF or start treatment from a different class of drugs, such as rituximab (RTX). It remains unclear in which clinical settings these therapeutic strategies offer most benefit. OBJECTIVE: To analyse the effectiveness of RTX versus alternative aTNFs on RA disease activity in different subgroups of patients. METHODS: A prospective cohort study of patients with RA who discontinued at least one aTNF and subsequently received either RTX or an alternative aTNF, nested within the Swiss RA registry (SCQM-RA) was carried out. The primary outcome, longitudinal improvement in 28-joint count Disease Activity Score (DAS28), was analysed using multivariate regression models for longitudinal data and adjusted for potential confounders. RESULTS: Of the 318 patients with RA included; 155 received RTX and 163 received an alternative aTNF. The relative benefit of RTX varied with the type of prior aTNF failure: when the motive for switching was ineffectiveness to previous aTNFs, the longitudinal improvement in DAS28 was significantly better with RTX than with an alternative aTNF (p = 0.03; at 6 months, -1.34 (95% CI -1.54 to -1.15) vs -0.93 (95% CI -1.28 to -0.59), respectively). When the motive for switching was other causes, the longitudinal improvement in DAS28 was similar for RTX and alternative aTNFs (p = 0.40). These results were not significantly modified by the number of previous aTNF failures, the type of aTNF switches, or the presence of co-treatment with a disease-modifying antirheumatic drug. CONCLUSION: This observational study suggests that in patients with RA who have stopped a previous aTNF treatment because of ineffectiveness changing to RTX is more effective than switching to an alternative aTNF.

A recursive presentation for Mihailova's subgroup

"Vegeu el resum a l'inici del document del fitxer adjunt."

The effectiveness and safety of rescue treatments in 108 patients with steroid-refractory ulcerative colitis with sequential rescue therapies in a subgroup of patients.

BACKGROUND: Among patients with steroid-refractory ulcerative colitis (UC) in whom a first rescue therapy has failed, a second line salvage treatment can be considered to avoid colectomy. AIM: To evaluate the efficacy and safety of second or third line rescue therapy over a one-year period. METHODS: Response to single or sequential rescue treatments with infliximab (5mg/kg intravenously (iv) at week 0, 2, 6 and then every 8weeks), ciclosporin (iv 2mg/kg/daily and then oral 5mg/kg/daily) or tacrolimus (0.05mg/kg divided in 2 doses) in steroid-refractory moderate to severe UC patients from 7 Swiss and 1 Serbian tertiary IBD centers was retrospectively studied. The primary endpoint was the one year colectomy rate. RESULTS: 60% of patients responded to the first rescue therapy, 10% went to colectomy and 30% non-responders were switched to a 2(nd) line rescue treatment. 66% of patients responded to the 2(nd) line treatment whereas 34% failed, of which 15% went to colectomy and 19% received a 3(rd) line rescue treatment. Among those, 50% patients went to colectomy. Overall colectomy rate of the whole cohort was 18%. Steroid-free remission rate was 39%. The adverse event rates were 33%, 37.5% and 30% for the first, second and third line treatment respectively. CONCLUSION: Our data show that medical intervention even with 2(nd) and 3(rd) rescue treatments decreased colectomy frequency within one year of follow up. A longer follow-up will be necessary to investigate whether sequential therapy will only postpone colectomy and what percentage of patients will remain in long-term remission.

Notes on the biology of Amblyomma dissimile Kock, 1844 (Acari: Ixodida) on Bufo marinus (Linnaeus, 1758) from Brazil

Amblyomma dissimile is a common ectoparasite of cold blooded animals and is an accidental ectoparasite of some wild mammals. Details of the biology of specimens from the State of Amapá were studied in the laboratory in a humidity chamber at an average environmental temperature of 19.5 °C, using Bufo marinus as host for the time in Brazil. We also report the first record of this species in the State of Minas Gerais.